Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis

Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis

Summary: Oncogenic mutations in the EGFR gene account for 15–20% of lung adenocarcinoma (LUAD) cases. However, the mechanism for EGFR driven tumor development and growth is not fully understood. Here, using an mRNA expression profiling-based approach we identified betacellulin (BTC) as one the gene...

Full description

Bibliographic Details
Main Authors:	Suresh Chava, Suresh Bugide, Xuchen Zhang, Romi Gupta, Narendra Wajapeyee
Format:	Article
Language:	English
Published:	Elsevier 2022-05-01
Series:	iScience
Subjects:	Cell biology Cancer Transcriptomics
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589004222004813

Similar Items

Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
by: Suresh Chava, et al.
Published: (2021-07-01)

Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma
by: Parmanand Malvi, et al.
Published: (2022-08-01)

Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
by: Suresh Chava, et al.
Published: (2022-08-01)

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
by: Yixuan Gong, et al.
Published: (2007-10-01)

Outcomes of salvage lung resections in advanced EGFR‐mutant lung adenocarcinomas under EGFR TKIs
by: Ying‐Yuan Chen, et al.
Published: (2021-10-01)

Characterizing the secretome of EGFR mutant lung adenocarcinoma
by: Jennifer K. Luu, et al.
Published: (2024-01-01)

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma
by: Teng Li, et al.
Published: (2021-05-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019-11-01)

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
by: Shigeki Nanjo, et al.
Published: (2022-07-01)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
by: Hongjing Zang, et al.
Published: (2020-04-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
by: Ling Li, et al.
Published: (2020-09-01)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
by: Jiyun Lee, et al.
Published: (2022-12-01)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
by: Toshihide Nishimura, et al.
Published: (2020-08-01)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
by: Wensheng Zhou, et al.
Published: (2022-03-01)

Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
by: Mari Tone, et al.
Published: (2023-05-01)

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
by: Carolien Eggermont, et al.
Published: (2022-07-01)

The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis
by: Lawrence David Mason, et al.
Published: (2021-11-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
by: Daniel B Costa, et al.
Published: (2007-10-01)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
by: Fushun Fan, et al.
Published: (2021-02-01)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024-02-01)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01)

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
by: Keisuke Tabara, et al.
Published: (2012-01-01)

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
by: Woraseth Saifon, et al.
Published: (2022-09-01)

Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
by: Yun Jung Choi, et al.
Published: (2013-01-01)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
by: Dan Yan, et al.
Published: (2022-08-01)

Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
by: Ranjan Pathak, et al.
Published: (2021-09-01)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
by: Ullas Batra, MD, DM, et al.
Published: (2021-01-01)

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations
by: Puyu Shi, et al.
Published: (2019-05-01)

Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database
by: Guangsheng ZHU, et al.
Published: (2021-04-01)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
by: Tereza Vaclova, et al.
Published: (2021-03-01)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.
by: Yun Jung Choi, et al.
Published: (2019-01-01)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
by: Jia-Shiuan Ju, et al.
Published: (2023-11-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
by: Sook-hee Hong, et al.
Published: (2022-12-01)

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non–small-cell lung carcinoma
by: Hyoung-oh Jeong, et al.
Published: (2022-11-01)

EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
by: Min Yu, et al.
Published: (2022-06-01)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma
by: Po-Hsin Lee, et al.
Published: (2022-07-01)